Tr1x, Inc. | MedPath

Tr1X Secures $8 Million CIRM Grant to Advance Novel Cell Therapy for Graft-Versus-Host Disease

2 months ago

• Tr1X has received an $8 million grant from the California Institute for Regenerative Medicine to support its Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for preventing graft-versus-host disease in mismatched stem cell transplants. • The company has reported positive initial persistence and safety data in the first two patient cohorts of the TRX103 trial, with additional results expected later in 2025. • TRX103 represents a potentially transformative approach to preventing GvHD without the immunosuppression drawbacks of current treatments, potentially expanding access to curative therapies for patients without matched donors.